Loading stock data…
$2.19+0.02 (+1.16%)
XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases.
XBiotech Inc. in the Healthcare sector is trading at $2.19 with a market capitalization of $66M. The stock is currently near its 52-week low of $2.09, remaining 7.4% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$6.15M↑ | -$6.27M↑ | -$29.75M↓ | -$6.05M↑ | -$6.34M |
| Net Income | -$6.73M↓ | -$5.50M↑ | -$26.89M↓ | -$6.01M↓ | -$1.76M |
XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases. The company is also deve...